News about "IgA nephropathy "

Otsuka's Voyxact Phase 3 Trial Shows Long-Term Kidney Protection in IgA Nephropathy

Otsuka's Voyxact delivered significant long-term kidney function stabilization and reduced the risk of kidney failure in the Phase 3 VISIONARY trial, strengthening its potential as a disease-modifying treatment for IgA nephropathy.

IgA Nephropathy | 04/07/2026 | By News Bureau |  215

Viatris Reports Positive Phase 3 Results for VR-205 in IgA Nephropathy in Japan

Viatris reported positive Phase 3 results for VR-205 in Japanese adults with primary IgA nephropathy and plans to submit a New Drug Application (NDA) in Japan by the end of 2026.

IgA Nephropathy | 01/07/2026 | By News Bureau |  229

Chugai Files Regulatory Application in Japan for IgA Nephropathy Drug Sparsentan

Chugai Pharmaceutical has applied for regulatory approval in Japan for sparsentan, a dual-action oral therapy for IgA nephropathy. Clinical studies showed significant reductions in proteinuria and potential benefits in preserving kidney function, offering hope for patients with limited treatment options.

IgA Nephropathy | 20/06/2026 | By News Bureau |  159

AstraZeneca's Ultomiris Granted FDA Priority Review for Rare Kidney Disease IgAN

The US FDA has granted Priority Review to AstraZeneca’s supplemental application for Ultomiris in immunoglobulin A nephropathy, bringing the therapy closer to becoming the first C5 complement inhibitor approved for the rare kidney disease.

IgA Nephropathy | 16/06/2026 | By News Bureau |  123

Travere Therapeutics Receives USPTO Patent Allowance for Filspari Use in IgA Nephropathy

Travere Therapeutics has secured a Notice of Allowance from the USPTO for a patent application covering specific methods of using Filspari (sparsentan) in the treatment of IgA nephropathy, strengthening its rare kidney disease portfolio.

IgA Nephropathy | 29/05/2026 | By News Bureau |  167

Otsuka receives FDA accelerated approval for Voyxact in adults with IgA nephropathy

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the US FDA has granted accelerated approval for Voyxact (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.

IgA Nephropathy | 27/11/2025 | By Darshana |  501

Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia

Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.

IgA Nephropathy | 24/10/2025 | By Dineshwori |  593

Renalys Pharma Completes Patient Enrollment for Phase III Trial of Sparsentan in Japan

In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

IgA Nephropathy | 01/02/2025 | By Abha |  803

Novartis Presents Interim Analysis of atrasentan Phase III Data

Novartis has presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN).

IgA Nephropathy | 28/05/2024 | By Aishwarya |  820

Vertex Signs Agreement to Acquire Alpine Immune Sciences

Vertex Pharmaceuticals has signed a definitive agreement with Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

IgA Nephropathy | 11/04/2024 | By Aishwarya |  949